By: Ken Alltucker
USA TODAY Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.
Ken Alltucker is a Health Reporter at USA Today. He focuses on healthcare issues, including the healthcare system, alternative medicine, and medical specialties, while also covering relevant topics such as the FDA, data, and social issues. Ken's work has been featured in notable publications including the Detroit Free Press, Yahoo News, and The Arizona Republic.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ken Alltucker's coverage is heavily focused on health-related topics, particularly healthcare and pharmaceutical issues. He frequently cites data and government announcements to support his articles. To effectively reach out to him, consider providing insights supported by relevant data or offering perspectives on recent government announcements related to healthcare policies or regulations.
Additionally, since Ken focuses on national coverage in the United States, pitches should be tailored with this geographic focus in mind. If you have expertise in healthcare policy, medication pricing, patient rights advocacy or similar fields within the US context, your input could resonate well with his reporting.
This information evolves through artificial intelligence and human feedback. Improve this profile .